These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31855568)

  • 1. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor.
    Pratama MRF; Poerwono H; Siswodihardjo S
    J Basic Clin Physiol Pharmacol; 2019 Dec; 30(6):. PubMed ID: 31855568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR
    Shen J; Zhang T; Zhu SJ; Sun M; Tong L; Lai M; Zhang R; Xu W; Wu R; Ding J; Yun CH; Xie H; Lu X; Ding K
    J Med Chem; 2019 Aug; 62(15):7302-7308. PubMed ID: 31298540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor.
    Yang Z; Yang H; Ai Y; Zhang L; Li Z; Wan S; Xu X; Zhang H; Wu S; Zhang J; Zhang T
    Eur J Pharm Sci; 2020 Sep; 152():105463. PubMed ID: 32668314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking of 5-o-benzoylpinostrobin derivatives from
    Wiyono AS; Siswandono ; Diyah NW
    J Public Health Afr; 2023 Mar; 14(Suppl 1):2532. PubMed ID: 37492536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
    Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
    Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
    Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
    World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
    J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
    Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
    J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.
    Saldaña-Rivera L; Bello M; Méndez-Luna D
    J Biomol Struct Dyn; 2019 Oct; 37(17):4671-4684. PubMed ID: 30558477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADMET properties of novel 5-O-benzoylpinostrobin derivatives.
    Pratama MRF; Poerwono H; Siswodiharjo S
    J Basic Clin Physiol Pharmacol; 2019 Dec; 30(6):. PubMed ID: 31851612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
    Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
    Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and initial
    Fawwaz M; Mishiro K; Arwansyah A; Nishii R; Ogawa K
    Bioimpacts; 2024; 14(1):27774. PubMed ID: 38327635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR
    Wang Y; Lai H; Fan X; Luo L; Duan F; Jiang Z; Wang Q; Leung ELH; Liu L; Yao X
    Front Pharmacol; 2018; 9():728. PubMed ID: 30038571
    [No Abstract]   [Full Text] [Related]  

  • 16. Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
    Juchum M; Günther M; Döring E; Sievers-Engler A; Lämmerhofer M; Laufer S
    J Med Chem; 2017 Jun; 60(11):4636-4656. PubMed ID: 28482151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR.
    Carlino L; Christodoulou MS; Restelli V; Caporuscio F; Foschi F; Semrau MS; Costanzi E; Tinivella A; Pinzi L; Lo Presti L; Battistutta R; Storici P; Broggini M; Passarella D; Rastelli G
    ChemMedChem; 2018 Dec; 13(24):2627-2634. PubMed ID: 30457710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
    Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.